Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'.

Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy bridge' meeting, which was held in Naples on 4-5 December 2019. Highlights related to the immunological treatment of nonmelanoma skin cancer are the content of this article.

[1]  Jason M. Johnson,et al.  Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN) , 2019, Annals of Oncology.

[2]  C. Berking,et al.  Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC). , 2019, Journal of Clinical Oncology.

[3]  P. Petrow,et al.  Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN. , 2019, Journal of Clinical Oncology.

[4]  A. Hauschild,et al.  Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. , 2019, Journal of Clinical Oncology.

[5]  Ludmila V. Danilova,et al.  Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab , 2018, Journal of Immunotherapy for Cancer.

[6]  J. Grob,et al.  Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial , 2018, JAMA oncology.

[7]  A. Hauschild,et al.  PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.

[8]  J. Taube,et al.  Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358. , 2018 .

[9]  T. Olencki,et al.  Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  J. Utikal,et al.  Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. , 2018, European journal of cancer.

[11]  K. Peris,et al.  Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology , 2017, Aging and disease.

[12]  Melissa L. Johnson,et al.  Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study. , 2017 .

[13]  A. Hauschild,et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study , 2017, BMC Cancer.

[14]  G. Daniels,et al.  Rescue therapy with anti‐programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases , 2016, The British journal of dermatology.

[15]  A. Hauschild,et al.  Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma? , 2016, The Lancet. Oncology.

[16]  P. Googe,et al.  PD‐L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis , 2016, Journal of cutaneous pathology.

[17]  T. Loh,et al.  Basal Cell Carcinoma of the Dorsal Hand: An Update and Comprehensive Review of the Literature , 2016, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[18]  J. Becker,et al.  Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. , 2015, European journal of cancer.

[19]  I. Zalaudek,et al.  Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. , 2015, European journal of cancer.

[20]  R. Dummer,et al.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.

[21]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[22]  E. Rosenthal,et al.  Outcomes of Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma , 2011, Journal of skin cancer.

[23]  F. D. de Sauvage,et al.  Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. , 2009, Trends in pharmacological sciences.

[24]  M. Scott,et al.  Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. , 1998, The Journal of investigative dermatology.

[25]  Michael Dean,et al.  Is human patched the gatekeeper of common skin cancers? , 1996, Nature Genetics.